Zobrazeno 1 - 10
of 269
pro vyhledávání: '"L, Poissonnier"'
Autor:
J.-J. Patard, H. Baumert, H. Lang, N. Rioux-Leclercq, L. Poissonnier, Bernard Escudier, J.-M. Correas, Y. Neuzillet, P. Paparel, J. A. Long, A. Mejean
Publikováno v:
Progrès en Urologie. 19:S129-S132
Resume Le traitement du CRM chez les sujets âges est identique a celui des patients plus jeunes. Alors que les cytokines etaient classiquement contrindiquees chez les patients de plus de 70 ou 75 ans (notamment l’IL2), les nouvelles therapeutiques
Publikováno v:
Revue des Maladies Respiratoires. 26:499-504
Introduction L’incontinence urinaire d’effort, dont la prevalence est estimee a 10-30 % dans la population feminine, peut avoir un retentissement psychosocial majeur. Dans les pneumopathies interstitielles diffuses (PID), la toux chronique peut f
Autor:
Liu, Jiafei1,2,3 (AUTHOR), Yang, Hongjie1,2,3 (AUTHOR), Li, Peng1,2,3 (AUTHOR), Zhou, Yuanda1,2,3 (AUTHOR), Zhang, Zhichun1,2,3 (AUTHOR), Zeng, Qingsheng1,2,3 (AUTHOR), Zhang, Xipeng1,2,3 (AUTHOR), Sun, Yi1,2,3 (AUTHOR) sunyi@vip.tom.com
Publikováno v:
Scientific Reports. 10/10/2024, Vol. 14 Issue 1, p1-13. 13p.
Autor:
Yang, Mingchuan1 (AUTHOR) yangmingchuan@tricaas.com, He, Yufeng1 (AUTHOR) qhyf2019@yeah.net, Ni, Qingqing2 (AUTHOR) 13671733209@163.com, Zhou, Mengxue1 (AUTHOR) zhoumengxue@tricaas.com, Chen, Hongping1 (AUTHOR) thean27@tricaas.com, Li, Guangyun1 (AUTHOR) fqcyzx@163.com, Yu, Jizhong3 (AUTHOR) hchyu@126.com, Wu, Ximing4 (AUTHOR) hchyu@126.com, Zhang, Xiangchun1 (AUTHOR) zhangxc@tricaas.com
Publikováno v:
Pharmaceutics. Aug2024, Vol. 16 Issue 8, p972. 20p.
Autor:
Wan, Zurong1,2 (AUTHOR), Gu, Jinghua1,2 (AUTHOR), Balaji, Uthra1,2 (AUTHOR), Bojmar, Linda3,4 (AUTHOR), Molina, Henrik5 (AUTHOR), Heissel, Søren5 (AUTHOR), Pagano, Alexandra E.5 (AUTHOR), Peralta, Christopher5 (AUTHOR), Shaashua, Lee3 (AUTHOR), Ismailgeci, Dorina6 (AUTHOR), Narozniak, Hope K.6 (AUTHOR), Song, Yi7 (AUTHOR), Jarnagin, William R.7 (AUTHOR), Kelsen, David P.6 (AUTHOR), Bromberg, Jaqueline6,8 (AUTHOR), Pascual, Virginia1,2 (AUTHOR) vip2021@med.cornell.edu, Zhang, Haiying3 (AUTHOR) haz2005@med.cornell.edu
Publikováno v:
Journal of Extracellular Biology. Jul2024, Vol. 3 Issue 7, p1-28. 28p.
Autor:
Wang, Shengqi1,2,3,4,5,6 (AUTHOR), Li, Jing3,4 (AUTHOR), Xu, Shang3,4 (AUTHOR), Wang, Neng4,6,7 (AUTHOR), Pan, Bo3,4 (AUTHOR), Yang, Bowen3,4 (AUTHOR), Zheng, Yifeng1,3,4,6 (AUTHOR), Zhang, Juping1,3,4,6 (AUTHOR), Peng, Fu8 (AUTHOR), Peng, Cheng2 (AUTHOR) pengchengchengdu@126.com, Wang, Zhiyu1,3,4,5,6 (AUTHOR) wangzhiyu@gzucm.edu.cn
Publikováno v:
Journal of Extracellular Vesicles. Jul2024, Vol. 13 Issue 7, p1-27. 27p.
Publikováno v:
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 22(7)
In the latest guidelines of the European Association of Urology, partial nephrectomy was a reference standard in tumors less than 7cm confined to the kidney. The invasion of the perirenal fat and therefore dissection in a potentially tumor tissue wit
Autor:
J-J, Patard, H, Baumert, J-M, Corréas, B, Escudier, H, Lang, J-A, Long, Y, Neuzillet, P, Paparel, L, Poissonnier, N, Rioux-Leclercq, M, Soulié
Publikováno v:
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 20
Autor:
S, Crouzet, L, Poissonnier, F-J, Murat, G, Pasticier, O, Rouvière, F, Mège-Lechevallier, J-Y, Chapelon, X, Martin, A, Gelet
Publikováno v:
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 21(3)
To report the functional and oncological outcomes of HIFU for prostate cancer using the Ablatherm Integrate Imaging(®) device.Between January 2005 and June 2009, all patients treated with HIFU as a primary care option for localized prostate cancer a
Autor:
J-J, Patard, B, Escudier, P, Paparel, Y, Neuzillet, J-A, Long, H, Baumert, J-M, Correas, H, Lang, L, Poissonnier, N, Rioux-Leclercq, M, Soulié
Publikováno v:
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 20
During the recent congress of urology and oncology key topics discussed were the evolution of survival data in metastatic kidney cancer which median is now around 40 months, persistent questions about the role of nephrectomy, including access to the